Krebs Biochemicals & Industries Ltd. AI Stock Analysis
Want to see IN:KREBSBIO full AI Analyst Report?
Krebs Biochemicals & Industries Ltd. (KREBSBIO) AI Stock Analysis
Krebs Biochemicals & Industries Ltd.
(NSE:KREBSBIO)
The low score is driven primarily by weak financial performance with persistent losses, negative equity, and cash burn. Bullish technical signals from price above moving averages provide limited support, while negative P/E weighs on valuation.
Krebs Biochemicals & Industries Ltd. (KREBSBIO) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 1.27B
- Dividend Yield
- ―
- Average Volume (3M)
- 3,928
- Price to Earnings (P/E)
- -9.5
- Beta (1Y)
- 1.00
- Revenue Growth
- -1.32%
- EPS Growth
- 51.41%
- Country
- India
- Employees
- 142
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Krebs Biochemicals & Industries Ltd. Business Overview & Revenue Model
Company Description
Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by developing...
How the Company Makes Money
KREBSBIO primarily makes money by manufacturing chemical products and selling them to customers, generating revenue from product sales (typically recognized upon dispatch/delivery under customer contracts). Its earnings are driven by (a) sales volume...
Krebs Biochemicals & Industries Ltd. Financial Statement Overview
Summary
Persistent net losses, declining revenue, negative equity, and ongoing cash burn signal high financial risk and operational challenges in a competitive pharma sector.
Income Statement
20Very NegativeBalance Sheet
10Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 268.57M | 237.32M | 433.12M | 504.21M | 521.34M | 597.03M |
| Gross Profit | 124.25M | 65.30M | 377.56M | -80.63M | 244.19M | -57.64M |
| EBITDA | 3.35M | -34.24M | -143.21M | -82.73M | -151.62M | -328.46M |
| Net Income | -133.49M | -169.33M | -269.39M | -197.28M | -246.92M | -445.27M |
Balance Sheet | ||||||
| Total Assets | 1.59B | 1.63B | 1.69B | 1.78B | 1.75B | 1.90B |
| Cash, Cash Equivalents and Short-Term Investments | 1.26M | 1.29M | 3.38M | 1.37M | 858.00K | 1.01M |
| Total Debt | 2.27B | 2.25B | 2.12B | 2.39B | 1.83B | 1.88B |
| Total Liabilities | 3.29B | 3.26B | 3.15B | 2.97B | 2.74B | 2.65B |
| Stockholders Equity | -1.71B | -1.63B | -1.46B | -1.19B | -994.62M | -750.93M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -121.78M | -114.54M | -70.50M | -355.84M | -407.36M |
| Operating Cash Flow | 0 | -90.06M | -78.91M | 23.65M | -247.13M | -172.16M |
| Investing Cash Flow | 0 | -36.36M | -49.70M | -78.17M | -126.45M | -229.00M |
| Financing Cash Flow | 0 | 126.30M | 128.65M | 55.64M | 373.43M | 395.06M |
Krebs Biochemicals & Industries Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KREBSBIO, the sentiment is Positive. The current price of 59.00 is above the 20-day moving average (MA) of 57.71, above the 50-day MA of 57.88, and above the 200-day MA of 57.57, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 52.79 is Neutral, neither overbought nor oversold. The STOCH value of 64.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KREBSBIO.
Krebs Biochemicals & Industries Ltd. Peers Comparison
Overall Rating
IN:PAR73Outperform
IN:BALPHARMA57Neutral
IN:ALPA47Neutral
IN:BIOFILCHEM47Neutral
IN:VIVIMEDLAB46Neutral
IN:KREBSBIO46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 1.42B | 10.94 | ― | ― | 9.40% | 34.12% | |
| 57Neutral | INR 1.36B | 17.35 | ― | 1.40% | 18.79% | -2.58% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 47Neutral | INR 1.11B | 31.43 | ― | ― | 0.46% | -83.31% | |
| 47Neutral | INR 500.74M | 103.72 | ― | ― | 9.31% | -82.71% | |
| 46Neutral | INR 456.03M | -0.24 | ― | ― | -39.80% | -452.04% | |
| 46Neutral | INR 1.27B | -9.50 | ― | ― | -1.32% | 51.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:KREBSBIO | Krebs Biochemicals & Industries Ltd. | 59.00 | -8.85 | -13.04% | |
| IN:ALPA | Alpa Laboratories Limited | 52.85 | -25.63 | -32.66% | |
| IN:BALPHARMA | Bal Pharma Limited | 85.60 | 8.80 | 11.46% | |
| IN:BIOFILCHEM | Biofil Chemicals & Pharmaceuticals Ltd. | 30.77 | -8.67 | -21.98% | |
| IN:PAR | Par Drugs and Chemicals Limited | 115.54 | 22.71 | 24.46% | |
| IN:VIVIMEDLAB | Vivimed Labs Limited | 5.50 | 0.60 | 12.24% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026
